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Abstract 23 
In recent years, three-dimensional (3D) cell culture models of the small intestine 24 
have gained much attention. These models support cell proliferation, migration, and 25 
differentiation, and encourage tissue organization which is not possible in two-26 
dimensional (2D) culture systems. Furthermore, the use of a wide variety of cell 27 
culture scaffolds and support substrates have revealed considerable differences in 28 
cell behavior and tissue organization. These systems have been used in combination 29 
with intestinal stem cells, organoid units or human colonic adenocarcinoma cell lines 30 
such as Caco-2 and HT29-MTX to generate a number of in vitro and in vivo models 31 
of the intestine. Here, we review the current 2D and 3D tissue engineering models of 32 
the intestine to determine the most effective sources of intestinal cells and current 33 
research on support scaffolds capable of inducing the morphological architecture 34 
and function of the intestinal mucosa.  35 
Keywords 36 
Stem cells, Organoid units, Tissue engineering, Caco-2 cells, HT29-MTX cells.  37 
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Introduction 42 
Until recently, in vitro intestinal models have been restricted to simple two-43 
dimensional (2D) cell culture on standard cell-culture plates or transwell culture 44 
inserts1. However, three-dimensional (3D) cell culture models are currently under 45 
investigation by groups worldwide to determine if these 3D cell cultures can more 46 
closely mimic the in vivo environment and support cell differentiation and 3D tissue 47 
organization which is not possible in conventional 2D cell culture systems2–7. These 48 
3D cell culture models have been evaluated for their use in tissue engineering and 49 
drug discovery8,9 and used as an alternative to in vivo animal models in drug toxicity 50 
studies10–12.  51 
Tissue engineering studies have promised an improved understanding of small 52 
intestinal physiology, as well as the response of the small intestine to infection, 53 
toxicity and new therapies13. Furthermore, using these systems may be possible to 54 
develop personalized intestinal tissue grafts which can be used to repair the intestine, 55 
whilst avoiding the risks of immune system rejection14. The most important element 56 
for successful tissue engineering of the small intestine is the use of specialized 57 
biomaterial scaffolds providing cells a substrate for the deposition of extracellular 58 
matrix and subsequent cell adhesion9,15,16. These scaffolds are often designed to 59 
biodegrade after the deposition of extracellular matrix, when the cells become 60 
mechanically independent14,17 and could be potentially used therapeutically18, 61 
however matching the degradation rates to synthesis and deposition of new matrix 62 
remains a key challenge in tissue engineering19–21. This article aims to review 2D 63 
and 3D cell culture systems used to culture intestinal cells, to determine whether the 64 
use of 3D scaffolds can mimic the in vivo environment. Furthermore, recent progress 65 
in establishing intestinal stems cells and organoid units in vitro and in vivo.   66 
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The architecture of the small intestine 67 
The small intestine is essentially a tube, which can be divided into four anatomically 68 
and functionally distinct layers: mucosa, submucosa, muscularis externa, and 69 
serosa22 (Figure 1). The mucosa is folded into villi which increases the surface area 70 
and maximizes digestion and absorption. The number of villi varies, depending on 71 
the position along the length of the intestine22, with the highest frequency seen in the 72 
proximal jejunum, which decreases towards the ileum. Furthermore, the villi 73 
morphology differs through the small intestine, decreasing in size from the proximal 74 
to the distal end of the small intestine. In the duodenum, the villi are leaf-like, whilst 75 
those of the jejunum and ileum having a tongue-like, and then finger-like 76 
appearance, respectively. At the base of the villi are crypts of Lieberkuhn23. These 77 
crypts are tubular glands which descend into underlying muscularis mucosa24 and 78 
form the intestinal stem cell niche (Figure 1). This complex villi rich mucosa layer is 79 
supported by the underlying submucosa, which is composed of fibrous connective 80 
tissue and a rich supply of blood and lymphatic vessels and is innervated by the 81 
Meissner's nervous plexus. Beneath the submucosa is the muscularis externa, 82 
composed of an inner circular and outer longitudinal smooth muscle layers 83 
innervated by the Auerbach's plexus, which enables the peristaltic movement of food 84 
along the intestine17. This layer is finally supported by a single layer of mesothelium 85 
called the serosa22 (Figure 1). 86 
Intestinal epithelial cell types  87 
The intestinal mucosa contains six main cell types, each with a specialized function. 88 
The most abundant are the specialized columnar epithelial cells or enterocytes which 89 
are highly polarized cells with tiny microvilli on their apical surface (Figure 1). These 90 
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enterocytes are responsible for producing of digestive enzymes and the absorption 91 
of nutrients22,25,26. The second most abundant cell types are unicellular glandular 92 
cells known as mucus-secreting goblet cells. Mucins are secreted into the lumen of 93 
the intestine by these goblet cells, giving rise to an adherent mucus layer which 94 
surrounds and coats the intestinal villi23. Located at the base of intestinal crypts are 95 
paneth cells, which secrete antimicrobial lysozymes protecting the crypt from 96 
pathological microorganisms26,27. These paneth cells also play an essential role in 97 
stem cell niche signals28,29. There are also smaller populations of hormone-secreting 98 
enteroendocrine cells and tuft cells which regulate digestion and absorption (Figure 99 
1). Finally, microfold or M-cells are located within lymphoid peyer's patches and are 100 
responsible for transporting antigens from the lumen to the underlying lymphoid 101 
tissues25,26.   102 
Importantly, a small population of stem cells are located at the villus base within 103 
crypts and are responsible for maintaining intestinal epithelial homeostasis (Figure 1). 104 
These stem cells differentiate as they migrate along the length of the villi, replacing 105 
cells which are lost at the villus tip. This process of cell renewal ensures that the 106 
functions of the intestinal epithelium are maintained throughout life. The capability of 107 
these stem cells to undergo self-renewal makes them particularly attractive for tissue 108 
engineering and regenerative medicine applications23. 109 
 110 
Why do we need to engineer a small intestine? 111 
The small intestine becomes dysfunctional in a number of diseases including 112 
inflammatory driven pathologies (such as ulcerative colitis; Crohn's disease; celiac 113 
disease), congenital diseases (such as lactose intolerance and short bowel 114 
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syndrome) and cancer. These can become extremely debilitating disorders 115 
impacting on quality of life or even life threatening30–32. Thus, the ability to replace 116 
damaged and malfunctioning tissues with a tissue-engineered small intestine could 117 
be of use in these conditions. Furthermore, engineered intestinal tissue could be 118 
created using patient-specific explants; small samples of healthy tissue could be 119 
collected from a patient and expanded within the laboratory. If these cells could then 120 
be utilized in the generation of a tissue-engineered small intestine, this could then be 121 
returned to the patient to enable intestinal repair or augmentation. Use of self-tissue 122 
would avoid the requirement of tissue donors, and the need for lifelong 123 
immunosuppression to prevent rejection of tissues33.  124 
2D cell culture models of the small intestine 125 
The use of cell lines in intestinal engineering  126 
Due to failed attempts to establish long-term primary cell culture of normal small 127 
intestine, researchers have successfully utilized cell lines which are derived from 128 
gastrointestinal tumours34. The human colonic adenocarcinoma cell lines (Figure 2): 129 
Caco-2 and HT29-MTX cells are probably the most frequently used cell lines due to 130 
their ability to differentiate into enterocyte-like cells and mucus-producing goblet 131 
cells, respectively35–37, whilst these would not be suitable for tissue enginering 132 
applications due to their cancerous nature they are excellent models for in vitro 133 
cultures.  134 
Caco-2 cells can spontaneously differentiate into cells with the ability to form tight 135 
junctions and produce large amounts of digestive brush border enzymes, similar to 136 
small bowel enterocytes38–40. Caco-2 cells express a number of digestive enzymes 137 
including sucrase-isomaltase, lactase, peptidase, and alkaline phosphatase. The 138 
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expression of these enzymes are used as markers of intestinal differentiation and 139 
digestive function41–47. However, Caco-2 cells have tight junctions similar to those of 140 
the colon, rather than the small intestine, this has led to criticism of their use as a 141 
model for the epithelium of the small intestine48,49. Furthermore, Caco-2 cell 142 
behaviour can be affected by culture condition (serum supplemented and serum free 143 
media), passage number, cell density and incubation times50,51 all of which make it 144 
difficult to compare research findings between different studies52,53. 145 
Caco-2 cells are often used to mimic small intestinal enterocytes and have been 146 
used extensively in absorption and transport studies of nutrients and drugs54,55, for 147 
example, insulin transport studies56,57. Moreover, Caco-2 cells have been used to 148 
investigate the cytotoxicity of acrylic-based copolymer protein as an oral insulin 149 
delivery system57. Caco-2 cells can also be utilized to verify the toxicology when 150 
exposed to nanoparticles such as polystyrene, which resulted in increased level of 151 
iron absorption58.  152 
HT29-MTX cells are also a commonly used cell line in intestinal modeling. These 153 
cells are derived from human colonic adenocarcinoma cells and are resistant to 154 
methotrexate (MTX). HT29-MTX cells are composed entirely of differentiated mucus-155 
secreting goblet cells. They maintain this differentiated phenotype in monolayer 156 
culture and are used to mimic intestinal goblet cells, and are commonly co-cultured 157 
with Caco-2 cells59–62. HT29-MTX cells have been utilized in studies investigating the 158 
diffusion of drugs across the mucus layer63–65, these have been used to test the 159 
mucoadhesive and toxicity of nanoparticles as drug delivery systems66, and to test 160 
adhesion and invasion of Salmonella strains67 (Table 1). 161 
2D co-culture studies  162 
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In order to mimic the native small intestinal epithelium which is composed of diverse 163 
absorptive and secretory cells a number of studies have co-cultured Caco-2 cells 164 
alongside HT29-MTX cells63,64,68–71. These studies have enabled the formation of a 165 
Caco-2 derived enterocyte-like layer, which is interspersed with mucus secreting 166 
HT29-MTX cells, and avoided the limitations and drawbacks previously seen in 167 
mono-cultures63. Walter et al., (1996) co-cultured Caco-2 and HT29-MTX cells in cell 168 
culture inserts in a transwell format, where they were shown to produce an adherent 169 
mucus layer which covered the cell monolayer. The cells were shown to have 170 
structures similar to microvilli, although they were of irregular shape and size63. The 171 
mucus layer formed by the HT29-MTX cells during co-culture with Caco-2 cells were 172 
proposed to play an important role in digestion and bioavailability68. Many studies 173 
have exploited in vitro co-cultures of Caco-2 and HT29-MTX cells to provide a drug 174 
absorption model63,68, to study drug permeability56,64,70,71 and to improve alternative 175 
in vitro systems for evaluation cytotoxicity of nanoparticles to replace animal testing72. 176 
Furthermore, different co-culture ratios of Caco-2 and HT29-MTX cells have been 177 
used to investigate the co-culture ratio most physiologically relevant to in vivo 178 
situations52,70,73,74.    179 
Another significant aspect of co-culture is the facility to introduce additional cell types 180 
to more closely mimic the native multicellular environment seen in vivo. Antunes et 181 
al., (2013), developed the triple co-culture model based on the use of Caco-2 and 182 
HT29-MTX cells, incorporating Raji B lymphocytes. The Raji B lymphocytes were 183 
selected to stimulate differentiation of Caco-2 cells to M-cells49,75,76. This triple co-184 
culture system was used to investigate absorption of insulin, demonstrating insulin 185 
permeability was greater in triple co-cultures compared to co-culture of Caco-2 and 186 
Raji B cells alone75. Moreover, in vitro triple co-culture model has been used for 187 
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polystyrene nanoparticle permeability studies that demonstrated the strong influence 188 
of HT29-MTX cells and M-cells on the nanoparticle permeation. In this study, cellular 189 
uptake of polystyrene nanoparticles was affected by the presence of mucus layers. 190 
Where, nanoparticle transport was significantly increased in Caco-2/M cells due to a 191 
lack of mucus secretion from M cells77. Most recently, the Caco-2/HT29-MTX co-192 
culture and Caco-2/HT29-MTX/Raji B triple co-culture models have been 193 
successfully used to investigate the intestinal permeability of different 194 
biopharmaceutical characteristics of drugs. Where it was shown that higher 195 
permeability of drugs were observed in more complex models compared with Caco-2 196 
monoculture76. Taken together, these studies demonstrated the importance of cell-197 
cell interactions which can impact on the physiological function in intestinal cells. 198 
These models can also be combined with bacterial cells to mimic the microbiotia 199 
seen within the small intenstine6,78,79. 200 
Whilst these 2D static culture models of intestinal cells in Transwells display a 201 
number of advantages, these models fail to develop villi morphology80. Furthermore, 202 
these models fail to undergo cytodifferentiation due to lack of the 3D 203 
microenvironment, including luminal flow, and fluid shear stress80,81.   204 
3D cell culture models of the small intestine 205 
A major shortcoming of the research utilizing intestinal cells in 2D culture is that it 206 
does not mimic the complex architecture of the small intestine and fails to mimic the 207 
in vivo phenotype. Thus, several biomaterial scaffolds have been investigated for 3D 208 
cell culture and tissue engineering of the small intestine15,46,82–84 (Table 2). These 209 
scaffolds provide a physical structure in which cells migrate and utilize topography to 210 
stimulate cell development and formation of tissue networks. Scaffold porosity is a 211 
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critical factor in directing cell fate within the 3D scaffold architecture. Pore size is 212 
essential for the diffusion of cells inside the 3D scaffolds, pores enable cells to 213 
penetrate into the matrix and provide a space for cells to reside and synthesize new 214 
extracellular matrix10,17,19,21,82. Accordingly, many attempts have been undertaken to 215 
develop porous biomaterials such as tubular constructs with mechanical and 216 
physical properties well suited to the small intestine4,85–89.  217 
The rate of cell growth, however, varies depending on the scaffold used90,91. In 3D 218 
cell culture models, the interaction between cells and the scaffold is regulated by the 219 
material characteristics of the scaffold. Some materials provide natural adhesion 220 
sites for cells whilst others provide a substratum for the deposition of extracellular 221 
matrix which subsequently provides adhesion sites for cells16. The mechanical 222 
characteristics and degradation dynamics of the scaffold are important for specific 223 
tissue engineering applications92,93. The mechanical properties of scaffolds control 224 
the shape of cells during tissue reconstruction and provide mechanical cues to cells 225 
to tailor differentiation17,82, whilst also providing support for load94. Scaffolds 226 
investigated to date include natural hydrogels (e.g. collagen gels and Matrigel) and 227 
synthetic scaffolds (e.g poly-lactic-glycolic acid) which have a number of key 228 
advantages and disadvantages.  229 
3D cell culture using collagen gels 230 
Type I collagen gels are commonly used for 3D culture, as they are easy to prepare, 231 
inexpensive, can support a range of cell types95,96, and enable encapsulation of 232 
cells97. Furthermore, pore size, rigidity, and ligand density can be adjusted by 233 
changing the collagen concentration or utilizing chemical cross-links94. Li et al., 234 
(2013) have used collagen gels to seed fibroblasts, Caco-2 and HT29-MTX cells. 235 
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This 3D triple co-culture model has been used to evaluate drug permeability and has 236 
been shown to have more physiologically relevant drug absorption rates96. Pusch et 237 
al., (2011) performed 3D co-culture of Caco-2 cells and human microvascular 238 
endothelial cells (hMECs), created multilayers of enterocyte-like cells which 239 
expressed villin, E-cadherin, and the transporter p-glycoprotein at levels that were 240 
similar to that of a normal human jejunum34. Whilst Viney et al., (2010) co-cultured 241 
intestinal epithelial cell lines (IEC6: a rat small intestinal epithelial cell line; IPI-21: a 242 
small boar ileum epithelial cell line, and CRL-2102: a human epithelial cell line 243 
derived from colorectal adenocarcinoma) with Rat-2 (fibroblast-like cell) in collagen 244 
gels alone or in combination with Matrigel. After 20 days, optimal epithelial cell 245 
growth was seen in collagen gels supplemented with Matrigel, where multilayered 246 
intestinal epithelium were seen, which included clusters of cells similar to the 247 
morphology of crypts98. This highlighted the importance of the interaction between 248 
the cell lines, extracellular matrix and other cell types such as fibroblasts; and how 249 
they can impact on the cell proliferation and differentiation99. These interactions with 250 
localized cells were further demonstrated when rat intestinal sub-epithelial 251 
myofibroblasts (ISEMF) were co-cultured with IEC-6 cells on a collagen gel 252 
scaffold100, where the myofibroblasts induced differentiation of IEC-6 intestinal cells 253 
to enteroendocrine cells, which was thought to be mediated by growth factors and 254 
cytokines secreted by the myofibroblasts100. 255 
A major shortcoming of these studies is that they do not reproduce the villus-crypt 256 
architecture of the small intestine. To overcome this shortcoming, Wang et al., 257 
(2009) investigated the effect of a biomimetic crypt-like microwell on Caco-2 258 
phenotype. A significant positive correlation between the crypt like topography and 259 
Caco-2 metabolic activity and migration with low level of differentiation which mimics 260 
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cells in crypts of native small intestine was observed101. In addition,  a number of 261 
studies have microfabricated villus-shaped collagen scaffolds into which Caco-2 cells 262 
were culutred82,83,102,103 (Table 2). These studies demonstrated that the culture of 263 
Caco-2 cells on these prefabricated villi structures led to the formation of villi which 264 
were comparable to those of human jejunum after 3 weeks in culture83. However, it 265 
has been observed that the transepithelial electrical resistance (TEER) of cells in 266 
these villus-like structures were lower than those in cells grown on 2D flat substrate.  267 
 268 
Synthetic Polymer  Scaffolds 269 
Synthetic scaffolds have also been studied for their ability to reconstruct the small 270 
intestine. Synthetic biodegradable copolymers: poly lactic acid(PLA) and poly 271 
glycolic acid (PGA) forming poly lactic glycolic acid (PLGA) have been investigated 272 
for scaffold fabrication in tissue engineering of the small intestine10,104. The chemical 273 
properties of PLGA co-polymer permitted hydrolytic degradation of the ester bond 274 
into the acidic, non-toxic monomers (PLA and PGA) which are removed by natural 275 
metabolic pathways. Physical properties of PLGA have been found to be related to 276 
the molecular weight of the monomers, the hydrophobic PLA/hydrophilic PGA ratio, 277 
the storage temperature and the exposure time to water. Demonstrating the rate of 278 
degradation negatively affected cell proliferation, with the fastest degradation rates 279 
displaying the poorest viability19,21.  280 
In addition, Costello et al., (2014) used fabricated PLGA as a porous 3D tissue 281 
scaffold which mimicked the shape and size of intestinal villi. They showed that co-282 
culture of Caco-2 and HT29-MTX on PLGA resulted in proliferation and 283 
differentiation of co-cultured cells. However, these Caco-2 and HT29-MTX cells were 284 
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differentiated under the stimulation of epidermal growth factor were added to the 285 
basolateral side of scaffolds82 (Table 2). Although the latest procedures to engineer 286 
the small intestine in vitro have been shown to have some positive outcomes, the 287 
surface area created is not adequate for human therapy and the majority of in vitro 288 
methods created only epithelium and lacked surrounding mesenchymal structures.  289 
Recapitulating the dynamic mechanical microenvironment of the small 290 
intestine 291 
Under in vitro static culture microenvironment, cells can be supplied with nutrients by 292 
manual medium replacement. Thus, long term culture under static conditions 293 
possesses multiple limitations such as poor delivery of nutrients, accumulation of 294 
waste and risk of contamination. To overcome these limitations, and for long term 295 
maintenance of intestinal cells in a healthy state, many studies have developed 296 
dynamic culture microenvironments.  297 
An automated perfusion system (Minucells and Minutissue) has been used to study 298 
the differentiation and drug transport properties of Caco-2 cells105,106. The enzymatic 299 
activities and permeability coefficient of drugs in differentiated Caco-2 cells in 300 
perfusion system were increased when compared to Caco-2 cells differentiated in 301 
traditional culture using snapwell inserts105,106.   302 
Similarly, microfluidic culture methods play an important role in addressing this issue 303 
and assist in the development of enhanced barrier function of Caco-2 cells107. 304 
Several studies have developed gut-on-a-chip microdevices to mimic the dynamic 305 
motion seen in the human small intestine80,81,108. Microfluidic gut-on-a-chip 306 
microdevices are an alternative in vitro model which have the ability to recapitulate 307 
the 3D structures of native human intestinal villi. In these models, Caco-2 cells 308 
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exposed to dynamic fluid flow and peristalsis-like motions resulted in 309 
cytodifferentiation of Caco-2 cells into four main types of intestinal epithelial cells and 310 
formed proliferative crypts80,81,108.    311 
Intestinal stem cell isolation and its importance in engineering the small 312 
intestine  313 
In recent years, there has been an increasing interest in Intestinal stem cells which 314 
are found at the base of the crypts within the proliferative compartment (Figure 1). 315 
These stem cells give rise to the four main cell lineages: enterocytes, goblet, 316 
enteroendocrine and paneth cells and are classified as crypt base columnar cells109–317 
111. Adult stem cells residing within the crypts have the ability to undergo cell 318 
proliferation into transit-amplifying progenitor (TA), which terminally differentiate and 319 
give rise to all six intestinal cell types of the mammalian intestine31,112–114. The 320 
proliferative capacity of these stem cells ensures there are sufficient cells to 321 
regenerate any damaged tissue115 and continually maintain digestion and absorption 322 
process.  These stem cells are ideal candidates for use in regenerative medicine116. 323 
The use of stem cell markers is essential for isolation of pure stem cell populations 324 
for use in tissue engineering. In the small intestine, there are two stem cell 325 
populations within the crypt, classified by location and cycling dynamics24,25,117. The 326 
first of these stem cells are cycling, slender cells found at the bottom of the crypt 327 
between paneth cells, these are known as crypt base columnar cells. These cells 328 
express several stem cell markers including Lgr5; CD133 (Prom1); Ascl2; Olfm4; 329 
Smoc2 and Sox9low 118–122. The second stem cell population are quiescent stem cells, 330 
which are located in the crypt directly above the terminally differentiated paneth 331 
cells123. These quiescent stem cells express Bmi-1, Hopx, mTert, and Lrig1, and 332 
Soxhigh 124,125. The locations where stem cells are located in the small intestine are 333 
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known as the stem cell niche, which is maintained by a range of cells (pericryptal 334 
myofibroblast, adjacent epithelial cells, immune cells (lymphocytes) endothelial cells, 335 
enteric neurons), which together with basement membrane derived extracellular 336 
matrix regulate stem cell differentiation and fate126–128. Several regulatory pathways 337 
play a role in the maintenance, and proliferation of stem cells24; these include:  Wnt; 338 
Notch; Hedgehog and bone morphogenetic protein (BMP) pathways129–131. 339 
Canonical Wnt signaling is well recognized as the main regulator of epithelial 340 
renewal in the small intestine118, with epidermal growth factor (EGF) signaling 341 
maintains stemness and prompts proliferation110,132,133. Whilst Notch signaling 342 
controls differentiation to enterocytes, inhibition of Notch signaling leads to the 343 
differentiation towards secretory lineages (including: goblet, paneth, enteroendocrine 344 
and tuft cells)134. Bone morphogenetic protein (BMP) signaling negatively regulates 345 
stem-cell characteristics and promotes differentiation of progenitor cells in the villus 346 
compartment, but has no effect on stem cells located in the crypts135. Thus the 347 
manipulation of these signaling pathways in vitro culture can be used to maintain 348 
stem-cell characterisitcs or drive differentiation of cells to appropriate lineages. 349 
For the successful extraction of stem cells from intestinal crypts a clear stem cell 350 
marker is essential to enable purification of intestinal stem cells, and whilst there are 351 
a variety of stem cells markers, Lgr5 (also known as GPR67) has been suggested 352 
the most appropriate marker for purification of stem cells23,24,26,28,116,120. Lgr5 is 353 
expressed in cycling columnar cells in the base of the crypts, but not in the villi116,136. 354 
Lgr5 is a target of Wnt signaling and these cells are capable of generating all 355 
epithelial lineages in in vitro culture 18,116,137. Furthermore, intestinal stem cells are 356 
capable of self-organizing into organoid units that recapitulate the intestinal villi and 357 
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crypt domains and reflect main structural and functional properties of the small 358 
intestine138,139.  359 
Intestinal organoids and tissue engineering of the small intestine  360 
3D cell culture of organoids  361 
Studies over the past two decades have provided promising results in tissue 362 
engineering of small intestine due to the successful isolation of intestinal crypts 363 
which could form organoid units (Figure 3). The ability to extract complete crypts, 364 
which contain progenitor cells, from intestinal tissues has excellent potential to 365 
expand in vitro to form organoid units and differentiate following transplantation. Kim 366 
et al., (2007) harvested neonatal rats intestinal epithelial organoid units and seeded 367 
them on biodegradable polyglycolic acid scaffolds and maintained them within a 368 
perfusion bioreactor for 2 days. The cells were shown to distribute and adhere to the 369 
polymer scaffold140. Sato and colleagues (2009) developed a 3D culture system of 370 
mouse intestinal crypt known as ‘mini-gut’ culture or organoid culture. These 3D 371 
cultures in Matrigel supplemented with growth factors (R-spondin-1, epidermal 372 
growth factor, and the BMP inhibitor: Noggin)18. In this system, the crypt-villus 373 
organoids developed not only from whole crypts but also from single Lgr5+ stem 374 
cells. These single intestinal stem cells were shown to form crypt-like structures by 375 
day 1-4, and then crypt-buds by day 518. In a similar studies conducted by Jabaji et 376 
al., (2013),(2014), compared type 1 collagen with Matrigel as an alternative scaffold 377 
for growing of isolated crypt units. They showed that the intestinal crypts enlarged 378 
and formed enteroids in vitro when cultured in both scaffolds as monoculture and 379 
when cultured with myofibroblast for 1 week141,142. Intestinal crypts not only isolated 380 
from human and mice but also isolated from juvenile and adult porcine. Khalil et al., 381 
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(2016) developed long-term culture model of juvenile and adult porcine intestinal 382 
crypts to generate budding enteroids143. More recently, Pastula et al., (2016), 383 
modified Sato's 3D culture methods using a combination of Matrigel and collagen 384 
and co-cultured the epithelial organoid with myofibroblast, and neuronal cells. Where 385 
myofibroblast and neuronal cells supported the growth of epithelial organoids. 386 
However, the presence of collagen led to a reduction in the budding of epithelial 387 
organoids7.  388 
A major disadvantage of these systems is they form closed organoid units, this has 389 
recently been overcome by Sachs et al., (2017), where tube formation was induced 390 
by culturing the organiods in a contracting floating collagen gel. They concluded that 391 
these systems enabled the organoids to align and fuse forming the macroscopic 392 
hollow structures. However this model although cellular differentiation was observed 393 
villi structures were still missing144, whilst Wang et al., (2017) has successfully 394 
generated crypt-villus architecture from intestinal stem cells cultured on a fabricated 395 
collagen scaffold145. Furthermore, application of chemical gradients which were 396 
applied to the scaffold promoted and supported cell migration along the crypt-villus 397 
axis145. Demonstrating a combined approach of microengineered scaffolds together 398 
with biophysical cues and chemical gradients could hold the potential for tissue 399 
engineering a small intestinal model in vitro145.   400 
In vivo implantation of organoid seeded scaffolds 401 
A number of studies have directly seeded these organoid units onto biodegradable 402 
scaffolds to test their ability to regenerate the intestine post-implantation in 403 
rodents85,146,147 and large animals148. In 1988, Vacanti et al., isolated organoid units 404 
from neonatal rat intestine and seeded these onto a tubular scaffold of polyglycolic 405 
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acid and poly-L-lactic acid prior to implantation into the omentum of the syngeneic 406 
adult rat. These organoid units survived, proliferated and had a characteristic villus-407 
crypt structures149. Choi and Vacanti, (1997) demonstrated that the organoid units 408 
isolated from 6-day-old neonatal rat intestines, seeded on PGA and then implanted 409 
into adult rats survived, proliferated, and regenerated small intestine-like 410 
structures146. Similarly, organoid units isolated from 7-week old Yorkshire swine and 411 
cultured on biodegradable scaffolds tubes and then implanted intraperitoneally in the 412 
autologous host. In these implants, differentiated intestinal cells innervated 413 
muscularis mucosa and intestinal sub-epithelial myofibroblasts were identified150. 414 
Levin et al., (2013) seeded multicellular organoid units derived from postnatal human 415 
small intestine resections onto a biodegradable PGA / PLA polymer151. Following 416 
transplantation into NOD/SCID gamma chain-deficient mice, the human tissue 417 
formed a villus-crypt architecture similar to that of the mature human small intestine, 418 
which contained all differentiated epithelial cell types and mesenchyme cells which 419 
expressing muscular and neural markers151. In vivo subcutaneous implantation using 420 
PGA scaffolds of one week old collagen based enteroids derived from 3D co-cultures 421 
of small intestinal crypts and myofibroblast resulted in sustainable re-formed 422 
intestinal organoids with differentiated lineages after 5 weeks141. Cromeens et al., 423 
(2016) produced neomucosa by seeding enteroids derived from LGR5-EGF 424 
transgenic mice on Matrigel for 10-14 day and then these enteroids released from 425 
Matrigel and seeded onto PGA scaffolds and implanted into the peritoneal cavity of 426 
immunocompromised NOD/SCID mice. After 4 weeks, neomucosa was produced 427 
with a clear crypt domains and blunted villi.  The shortcoming of this study was the 428 
villi were blunted and did not extend to the length of native small intestinal villi152. 429 
The main limitations of these attempts to generate small intestinal tissue are the high 430 
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number of cells required for engineering functional tissue and the absence of 431 
scaffolds which mimic the native intestine and capable of generating intestinal stem 432 
cell niche. 433 
3D cell culture of pluripotent stem cells 434 
Multipotent stem cells can generate numerous tissues in the body and have the high 435 
proliferative capacity, making them attractive for use in regenerative medicine153. 436 
Mesenchymal stem cells have been investigated as a promising source of smooth 437 
muscle layer for small intestinal tissue engineering.  Hori et al., (2002) investigated 438 
mesenchymal stem cells to study the feasibility of muscle regeneration, the 439 
limitations considered the lack of ability to regenerate smooth muscle layer154.  440 
Over recent years, several studies have provided evidence that human induced 441 
pluripotent stem cells (iPSCs) can be used to generate intestinal tissue147,155,156. A 442 
study published in 2011 aimed to direct the differentiation of human pluripotent stem 443 
cells to generate fetal intestinal-like immature properites using manipulation of 444 
growth factors155. Similary, Yoshida et al., (2012) demonstrated that mice pluripotent 445 
stem cells were successfully differentiated into smooth muscle in vitro157. Whilst, 446 
Watson et al., (2014) generated human intestinal organoids from human iPSCs. In 447 
this model, these organoids were embedded in collagen type I and then transplanted 448 
into immunocompromised mice for a period of 6 weeks. Following transplantation, 449 
iPSCs fully differentiated into all types of small intestinal cells and smooth muscle 450 
layers when compared with in vitro human intestinal organoids156. A recent study 451 
conducted by Finkbeiner et al., (2015) also has been shown that the human 452 
intestinal organoids derived from iPSCs generated a tissue that looks resemble the 453 
native human intestinal tissue when seeded onto PGA/PLA scaffolds and implanted 454 
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into immunocompromised mice for 12 weeks. While these promising findings, tissue 455 
engineered intestine were supplemented with further neuronal cell types to generate 456 
physiologically functional tissue engineered intestine147. 457 
Conclusion   458 
In spite of the current limitations, attempts at tissue engineering intestinal tissues in 459 
vitro have provided initial knowledge on the behaviour of intestinal cells in 2D and 3D 460 
culture (Figure 4&5) and the performance of stem cells and organoid units following 461 
implantation into animals. These models are extremely useful for the study of 462 
intestinal physiology, drug absorption studies and toxicity studies. However, to date, 463 
they fall short of successfully modeling the in vivo environment. Advanced studies 464 
and new approaches are required to provide intestinal tissue composed of mucosa 465 
and neuromuscular tissue before treatment of patients with intestinal failure can be 466 
achieved. The potential ability of stem cells to differentiate into many intestinal cell 467 
types provides the intestinal mucosa an amazing reconstruction capacity, and 468 
exploitation of this role might make it possible to treat a variety of intestinal diseases. 469 
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